BR112022020826A2 - Polipeptídeos il-12 e il-23 projetados e usos dos mesmos - Google Patents

Polipeptídeos il-12 e il-23 projetados e usos dos mesmos

Info

Publication number
BR112022020826A2
BR112022020826A2 BR112022020826A BR112022020826A BR112022020826A2 BR 112022020826 A2 BR112022020826 A2 BR 112022020826A2 BR 112022020826 A BR112022020826 A BR 112022020826A BR 112022020826 A BR112022020826 A BR 112022020826A BR 112022020826 A2 BR112022020826 A2 BR 112022020826A2
Authority
BR
Brazil
Prior art keywords
interleukin
methods
engineered
polypeptides
compositions
Prior art date
Application number
BR112022020826A
Other languages
English (en)
Inventor
Christopher Garcia Kenan
R Glassman Caleb
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BR112022020826A2 publication Critical patent/BR112022020826A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

POLIPEPTÍDEOS IL-12 E IL-23 PROJETADOS E USOS DOS MESMOS. A presente invenção refere-se geralmente a composições e métodos de modulação da transdução de sinal mediados pela interleucina-12 e interleucina-23. Em particular, a divulgação fornece novas variantes de interleucina-12 subunidade p40 com afinidade de ligação reduzida à IL-12Rß1. Também são fornecidas composições e métodos úteis para produzir tais variantes de polipeptídeo IL-12p40, bem como métodos para modular a sinalização mediada por IL-12p40, e/ou para o tratamento de condições associadas a perturbações da transdução de sinal mediada por IL-12p40.
BR112022020826A 2020-04-17 2021-04-16 Polipeptídeos il-12 e il-23 projetados e usos dos mesmos BR112022020826A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011742P 2020-04-17 2020-04-17
US202163150451P 2021-02-17 2021-02-17
PCT/US2021/027838 WO2021212083A2 (en) 2020-04-17 2021-04-16 Engineered il-12 and il-23 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
BR112022020826A2 true BR112022020826A2 (pt) 2022-11-29

Family

ID=78084508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020826A BR112022020826A2 (pt) 2020-04-17 2021-04-16 Polipeptídeos il-12 e il-23 projetados e usos dos mesmos

Country Status (11)

Country Link
US (1) US20230220031A1 (pt)
EP (1) EP4135780A4 (pt)
JP (1) JP2023521870A (pt)
KR (1) KR20230004646A (pt)
CN (1) CN115916261A (pt)
AU (1) AU2021255736A1 (pt)
BR (1) BR112022020826A2 (pt)
CA (1) CA3180340A1 (pt)
IL (1) IL297186A (pt)
MX (1) MX2022012823A (pt)
WO (1) WO2021212083A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023007607A (es) * 2020-12-23 2023-07-11 Immunowake Inc Inmunocitocinas y usos de estas.
TW202321282A (zh) * 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
WO2024006563A1 (en) * 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
TWI357336B (en) * 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
CA2962099A1 (en) * 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Also Published As

Publication number Publication date
AU2021255736A1 (en) 2022-11-03
MX2022012823A (es) 2023-01-04
JP2023521870A (ja) 2023-05-25
IL297186A (en) 2022-12-01
WO2021212083A2 (en) 2021-10-21
WO2021212083A3 (en) 2021-11-25
EP4135780A4 (en) 2024-06-05
KR20230004646A (ko) 2023-01-06
US20230220031A1 (en) 2023-07-13
CN115916261A (zh) 2023-04-04
CA3180340A1 (en) 2021-10-21
EP4135780A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
BR112022020826A2 (pt) Polipeptídeos il-12 e il-23 projetados e usos dos mesmos
DE60227361D1 (de) Computer vermitteltes assembly von polynucleotiden kodierend für ein zielgerichtetes polypeptide
MXPA05012316A (es) Peptidos novedosos que se unen al receptor de la eritropoyetina.
DE60218445D1 (de) Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
ATE435923T1 (de) Neue polynukleotide und polypeptide des erythropoietingens
DK1934353T3 (da) IL-15R alpha sushi domæner som en selektiv og effektiv forstærker af IL-15-virkningen gennem IL-15Rbeta/gamma, i hyperagonist IL-15 Ralpha sushi -IL 15 fusionsproteiner
ATE342976T1 (de) Cytokinrezeptor-kette
EE200300415A (et) Atsüülitud piperidiini derivaadid kui melanokortiin-4 retseptori agonistid ja farmatseutiline kompositsioon
ATE346600T1 (de) Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
MX2022014890A (es) Polipéptidos de interleucina-10 modificados y usos de los mismos.
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
WO2002077186A3 (en) Human secreted proteins
HK1060521A1 (en) Pharmaceuticals comprising the heat shock protein 10 (cpn 10) from my cobacterium tuberculosis.
BR112022020796A2 (pt) Polipeptídeos de interleucina-22 projetados e usos do mesmos
NZ315514A (en) Tumour necrosis factor associated factor (traf) inhibitors including traf polypeptide, murine nucleotide sequence and associated assays
WO2003087338A3 (en) Her-2 receptor tyrosine kinase molecules and uses thereof
DE60143959D1 (de) En kodieren
RU2020106669A (ru) Синтетические белки и пути их терапевтического применения
DK1816193T3 (da) Lignanglycosidase og udnyttelse deraf
EP2270164A3 (en) Recombinant protein variants
ATE270332T1 (de) Polynucleotide and polypeptide basb033 aus neisseria meningitidis und ihre verwendungen
DE602004001509D1 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
FI943146A0 (fi) Signaalipeptideistä vapaiden stafylokinaasien ilmentyminen
ZA202202180B (en) Engineered hcv e2 immunogens and related vaccine compositions